Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver tumor treatment gets a targeted boost: Drug-Loaded beads take aim at metastases

NCT ID NCT06311851

Disease control Sponsor: Pardis Noor Medical Imaging and Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new approach for people with liver metastases (cancer that has spread to the liver from elsewhere). Doctors are using a procedure called TACE to deliver the drug bevacizumab directly into the liver's blood vessels, aiming to concentrate the treatment where it's needed most. The study will enroll 40 participants to see if this method is safe and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bevacizumab (a drug that slows blood vessel growth) delivered directly to liver tumors via a procedure called TACE
What this could lead to
If successful, this could offer a new treatment option for people with liver metastases that haven't responded to other therapies.
What could go wrong
This is an early pilot study with only 40 participants, so results may not apply broadly. The combination of bevacizumab and TACE is new and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmation of metastatic liver cancer via histological examination or a characteristic imaging profile on dynamic computed tomography (CT) scan or magnetic resonance imaging (MRI) without indications for surgical resection * Eastern cooperative oncology group performance status (ECOGPS) of 0 or 1 * Liver function categorized as Child-Pugh class A or B * Stable non-hepatic metastases, such as skeletal, pulmonary, or lymph node metastases * Hepatic tumor burden below 70% * Expected survival duration exceeding six months * Laboratory findings meeting specific criteria, including platelet count \>50×109 /L, hemoglobin \>8.0 g/dL, ANC count ≥1.5 × 109/L, bilirubin \<51 mmol/L, alanine and aspartate aminotransferase \<3 times the upper limit of the normal range, and serum creatinine \<1.5 times the upper limit of the normal range. Exclusion Criteria: * Active infection * Presence of severe comorbidities, such as hepatic encephalopathy, refractory ascites, and esophageal variceal bleeding * Prior liver resection * Previous TACE therapy received at other healthcare facilities * Poor performance status (ECOGPS \> 1)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Liver metastases Metastatic cancer

Contacts and locations

Locations

  • Pardis Noor Medical Imaging and Cancer Center

    Tehran, Tehran Province, 021, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.